CAS No.51-40-1,L-NORADRENALINE BITARTRATE Suppliers

Products Categories

Pharmaceutical (22)
Others (14)
Organic Chemicals (2)
Catalyst and Auxiliary (1)

Basic Information

Molecular Structure:
CAS No.:	51-40-1
Name:	L-NORADRENALINE BITARTRATE

Formula:	C₈H₁₁NO₃^.C₄H₆O₆
Molecular Weight:	319.268
Synonyms:	l-Noradrenaline bitartrate;Levophed bitartrate;(-)-Noradrenaline acid tartrate;Benzyl alcohol, .alpha.- (aminomethyl)-3,4-dihydroxy-, (-)-, tartrate (1:1);(-)-Noradrenaline bitartrate;(-)-Norepinephrine bitartrate;Noradrenaline hydrogen tartrate;Noradrenaline tartrate;(-)-Norepinephrine (+)-bitartrate;Benzyl alcohol, .alpha.- (aminomethyl)-3,4-dihydroxy-, (-)-, tartrate (1:1) (salt);Noradrenaline bitartrate;1,2-Benzenediol, 4- (2-amino-1-hydroxyethyl)-, (R)-, [R-(R,R)]-2,3-dihydroxybutanedioate (1:1) (salt);Noradrenaline acid tartrate;Arterenol bitartrate;Norepinephrine bitartrate;(-)-Norepinephrine tartrate;(-)-Noradrenaline bitartrate monohydrate;Noradrenaline, tartrate (1:1);(-)-Noradrenaline hydrogen tartrate;(-)-Noradrenaline tartrate;Norartrinal bitartrate;l-Noradrenaline d-bitartrate;l-Arterenol bitartrate;Levarterenol bitartrate;1,2-Benzenediol,4-[(1R)-2-amino-1-hydroxyethyl]-,(2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt);(-)-Noradrenaline (+)-bitartrate;4-(2-amino-1-hydroxy-ethyl)benzene-1,2-diol; 2,3-dihydroxybutanedioic acid;Norepinephrine tartrate;
EINECS:	200-095-0
Melting Point:	102-104 °C
Boiling Point:	442.6 °C at 760 mmHg
Flash Point:	221.5 °C
Appearance:	White crystalline powder
PSA:	201.77000
LogP:	-1.33240

Synthetic route

: 42028-44-4
4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadecafluoro-undecan-1-al

: 51-40-1
norepinephrine bitartrate

: C30H21F34NO3

Conditions

Conditions	Yield
With 2-picoline borane complex In isopropyl alcohol at 20℃; for 0.25h;

Total:37 Page 1 of 1 1

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 51-40-1

Specification

The l-Noradrenaline tartrate, with the CAS registry number 51-40-1 and EINECS registry number 200-095-0, has the systematic name of 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol 2,3-dihydroxybutanedioate (1:1). It belongs to the product categories: Standards - 13C & 2H for GC-Mass Spectrometry. And the molecular formula of the chemical is C₈H₁₁NO₃^.C₄H₆O₆.

The characteristics of l-Noradrenaline tartrate are as followings: (1)ACD/LogP: -0.88; (2)# of Rule of 5 Violations: 1 ; (3)#H bond acceptors: 4; (4)#H bond donors: 5; (5)#Freely Rotating Bonds: 6; (6)Polar Surface Area: 30.93 Å²; (7)Flash Point: 221.5 °C; (8)Enthalpy of Vaporization: 73.79 kJ/mol; (9)Boiling Point: 442.6 °C at 760 mmHg; (10)Vapour Pressure: 1.3E-08 mmHg at 25°C.

Addtionally, the following datas could be converted into the molecular structure:
(1)SMILES: O=C(O)C(O)C(O)C(=O)O.Oc1ccc(cc1O)[C@@H](O)CN
(2)InChI: InChI=1/C8H11NO3.C4H6O6/c9-4-8(12)5-1-2-6(10)7(11)3-5;5-1(3(7)8)2(6)4(9)10/h1-3,8,10-12H,4,9H2;1-2,5-6H,(H,7,8)(H,9,10)/t8-;/m0./s1
(3)InChIKey: WNPNNLQNNJQYFA-QRPNPIFTBL

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
mouse	LD50	intraperitoneal	26800ug/kg (26.8mg/kg)		Dissertationes Pharmaceuticae et Pharmacologicae. Vol. 23, Pg. 435, 1971.
mouse	LD50	intravenous	1025ug/kg (1.025mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: DYSPNEA	European Journal of Pharmacology. Vol. 9, Pg. 289, 1970.
rat	LD50	intravenous	210ug/kg (0.21mg/kg)	SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 7, Pg. 627, 1979.
rat	LDLo	subcutaneous	3987ug/kg (3.987mg/kg)	BEHAVIORAL: EXCITEMENT	Journal of Pharmacology and Experimental Therapeutics. Vol. 95, Pg. 155, 1949.